SAS Output

27-OCT-2020 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G		 O
P
E
N		 ARM TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 ADMIN
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 1079 381 193 97 35 7 BREAST
        1079 381 193 97 35 7  
 
  2 Y 2 Observation 460 158 78 40 13 3  
      3 MK-3475 (Pembrolizumab) 465 165 85 42 14 1  
        925 323 163 82 27 4  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y 0 Screening 228 71 32 13 8 4 SURV
        228 71 32 13 8 4  
 
  2 Y 1 Carvedilol 40 10 2 1 0 0  
      2 No prophylaxis 43 15 8 3 0 0  
      3 Observation 126 33 14 6 1 1  
        209 58 24 10 1 1  
 
S1600-Bladder,Radical Cystectomy Outcomes Nutrition 1 T 1 Blinded Nutrition Drink 5 0 0 0 0 0 SXQOL
      2 Blinded Nutrition Drink 10 0 0 0 0 0  
        15 0 0 0 0 0  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 301 133 73 39 17 2 GU
      2 Tokyo-172 BCG 301 133 73 41 19 1  
      3 Prime + Tokyo-172 BCG 302 135 74 42 18 5  
        904 401 220 122 54 8  
 
S1614-HBV in Ca Pts, TAF vs SOC 1 T 4 SOC HBV Treatment 2 2 0 0 0 0 SXQOL
        2 2 0 0 0 0  
 
S1703-Met Breast, STM-monitoring v Usual Care 1 Y 0 Screening 186 103 59 41 13 1 CCD
        186 103 59 41 13 1  
 
  2 Y 1 Control (Usual Care) 50 29 17 10 4 2  
      2 Intervention (STMDDM) 50 29 15 7 4 0  
        100 58 32 17 8 2  
 
S1714-CIPN Risk Prediction Cohort Study, Taxanes 1 Y 1 Observation 484 410 215 131 54 10 SXQOL
        484 410 215 131 54 10  
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum 1 Y 0 Induction SST 253 131 70 33 14 2 GU
        253 131 70 33 14 2  
 
  2 Y 1 Standard Systemic Therapy Only 89 56 30 15 5 1  
      2 SST + Surgery/RT 89 56 28 17 3 0  
        178 112 58 32 8 1  
 
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab 1 Y 0 Initial Registration 108 92 46 19 9 1 GU
        108 92 46 19 9 1  
 
  2 Y 1 Chemo + RT 50 42 20 10 5 1  
      2 Chemo + RT + Atezolizumab 48 43 22 7 3 0  
        98 85 42 17 8 1  
 
S1820-Rectal, Diet modification to manage GI sx 1 Y 0 Run-In 36 36 33 14 5 1 PEOLC
        36 36 33 14 5 1  
 
  2 Y 1 Diet Modification Coaching 14 14 14 8 1 1  
      2 Healthy Living Education 11 11 10 3 1 0  
        25 25 24 11 2 1  
 
S1823-GCT, Obs. Cohort, miRNA371 1 Y 1 Observation 14 14 14 14 6 0 PREV
        14 14 14 14 6 0  
 
S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD 1 Y 1 Nivolumab + AVD 121 114 73 40 17 3 LYMPH
      2 Brentuximab Vedotin + AVD 118 111 66 41 18 1  
        239 225 139 81 35 4  
 
S1827-SCLC, MRI Surveillance +/- PCI 1 Y 1 PCI + MRI brain surveillance 9 9 9 7 4 0 LUNG
      2 MRI brain surveillance 9 9 9 4 2 0  
        18 18 18 11 6 0  
 
S1904-Breast, Decision making for chemoprevention 1 Y   0 0 0 0 0 0 PREV
        0 0 0 0 0 0  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 618 30 16 9 3 0 PREV
        618 30 16 9 3 0  
 
  1 Y 1 Blinded drug 109 16 9 7 0 0  
      2 Blinded drug 36 0 0 0 0 0  
      3 Blinded drug 35 0 0 0 0 0  
      4 Blinded drug 114 20 10 7 4 1  
        294 36 19 14 4 1  
 

27-OCT-2020 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Open Studies with No Registrations
S1904-Breast, Decision making for chemoprevention regtype: 1